Geode Capital Management
ARTV

Geode Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Geode Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$655K Buy
101,695
+578
+0.6% +$2.86K ﹤0.01% 3492
2025
Q4 		$434K Sell
101,117
-9,779
-9% -$36.9K ﹤0.01% 3637
2025
Q3 		$319K Sell
110,896
-48,145
-30% -$129K ﹤0.01% 3773
2025
Q2 		$240K Sell
159,041
-251,416
-61% -$528K ﹤0.01% 3813
2025
Q1 		$1.23M Buy
410,457
+94,699
+30% +$511K ﹤0.01% 3231
2024
Q4 		$3.18M Buy
315,758
+6,828
+2% +$82K ﹤0.01% 2959
2024
Q3 		$4.77M Buy
+308,930
New +$3.58M ﹤0.01% 2781

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Geode Capital Management's ARTV Position: Q1 2026 in Review

Geode Capital Management increased its Artiva Biotherapeutics (ARTV) stake by 0.57% in Q1 2026, buying an estimated $2.86K and bringing the position to 101,695 shares worth $655K. The position accounts for ﹤0.01% of the portfolio, ranked #3492.

Geode Capital Management first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $4.77M in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Geode Capital Management held 101,695 shares of Artiva Biotherapeutics worth $655K as of Q1 2026.
  • Geode Capital Management bought 578 Artiva Biotherapeutics shares in Q1 2026, an estimated $2.86K.
  • Artiva Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3492 holding.
  • Geode Capital Management first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • Geode Capital Management's Artiva Biotherapeutics position peaked at $4.77M in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.